AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
Study NCT00641732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
Study NCT01738061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Description: Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
Study NCT01578785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
Study NCT01524237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2979165
Description: Capsules administered orally
Study NCT01524237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Tablets administered orally
Study NCT01524237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01524237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intravenously (IV)
Study NCT01524237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Administered intravenously (IV)
Study NCT00890071 — intervention group
Intervention type: OTHER
Intervention: Fluid administration
Description: 500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
Study NCT01959399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral tablet
Study NCT01959399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral tablet
Study NCT02415764 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral/Attitudinal OnTrack Role-Playing Game
Description: The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys.
Study NCT02644148 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Roux-en-Y Gastrojejunostomy
Description: Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
Study NCT02644148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y Gastrojejunostomy
Description: Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
Study NCT00442676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Capsule, 200 mg/day until 32 weeks of gestation
Study NCT00442676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules of lactose
Study NCT01879319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AMD
Description: Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
Study NCT01879319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab AI/pen
Description: Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
Study NCT01722812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cromoglicate
Description: Twice daily topical treatment for 14 days
Study NCT01722812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Twice daily topical treatment for 14 days
Study NCT01933256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2B
Study NCT01933256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03516409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biokult
Description: Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: >1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each
Study NCT03516409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets.
Study NCT02067416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracycline based chemotherapy
Description: standard of care neoadjuvant treatment with anthracycline based chemotherapy
Study NCT02067416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane-based chemotherapy
Description: neoadjuvant taxane based chemotherapy given as standard of care
Study NCT04154696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation of a graft after assessment by normothermic perfusion
Description: Liver transplantation of a graft after assessment by normothermic perfusion
Study NCT00000450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Tablet
Study NCT00000450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Tablet
Study NCT03280069 — intervention group
Intervention type: DEVICE
Intervention: THERMIeyes® 20 RF System
Description: The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Vitamin D (Calcipotriol) application
Description: Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
Study NCT00512278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
Study NCT00512278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream application
Description: placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT02976727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
Study NCT02976727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study NCT02976727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study NCT02039011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol
Description: Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study NCT02976727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
Study NCT02976727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
Study NCT03886116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
Study NCT03772652 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements
Study NCT03340857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent electric bicycle (VELIS) sessions
Description: Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
Study NCT02976727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT02976727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT04141592 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Already clinically indicated surgical procedures
Study NCT01313832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
Study NCT02039011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and tiotropium
Description: Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study NCT01760577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (Allergan, Inc, Irvine CA)
Description: patients received intraarticular injections by the same experienced physician using aseptic procedures.
Study NCT01760577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan (Hyalgan, Fidia , Italy)
Description: The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
Study NCT02514343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 1ml of 10% magnesium sulfate with 1.5 ml of sterile water
Study NCT02514343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
Study NCT02035514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow autologous mesenchymal stem cells transplantation
Study NCT02443701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Warmup program, maximum isometric strengthening, and jump training
Study NCT02443701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LASER
Description: a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
Study NCT02443701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES
Description: electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
Study NCT02126163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
Study NCT01981798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and occupational therapy
Description: Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
Study NCT03736148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
Study NCT03736148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument-assisted Manipulation
Description: The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
Study NCT03736148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
Study NCT06084351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:
Study NCT06084351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for hospitalized COVID-19 patients
Study NCT03240107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levator resection
Description: The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene.
Study NCT03240107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levator tucking
Description: The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene.
Study NCT02581891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: 3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
Study NCT02581891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: 3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
Study NCT01058733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Internet
Description: new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
Study NCT03369366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive
Description: NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
Study NCT03369366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLS Martin Mandibular Reconstruction Implant
Description: The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).